Zozaya, NéboaArrizubieta Basterrechea, Maria IciarBollo, ElenaCastellví, IvánEspín, JaimeOrtego, NorbertoPoveda-Andrés, José LuisRodríguez Portal, José AntonioRivero, AgustínMarcos-Rodríguez, José AntonioVerde, Luis2023-05-032023-05-032022-08-01Zozaya N, Arrizubieta Basterrechea MI, Bollo E, Castellví I, Espín J, Ortego N, et al. A multi-criteria decision analysis on the value of nintedanib for interstitial lung diseases. Int J Technol Assess Health Care. 2022 Aug 1;38(1):e64.http://hdl.handle.net/10668/22578Our aim was to assess the value of nintedanib for non-idiopathic progressive fibrosing interstitial lung disease (non-IPF PF-ILD) and systemic sclerosis-associated ILD (SSc-ILD) in the Spanish context, using a multi-criteria decision analysis (MCDA). Following an adaptation of the Evidence and Value: Impact on DEcision Making (EVIDEM) MCDA methodology, the estimated value of nintedanib was obtained by means of an additive linear model that combined individual weights (100-points distribution) of criteria with the individual scoring of nintedanib in each criterion for every indication, assigned by a multidisciplinary committee of twelve clinicians, patients, pharmacists, and decision-makers. To assess the reproducibility, an alternative weighting method was applied, as well as a re-test of weights and scores at a different moment of time. The experts committee recognized nintedanib as an intervention with a positive value contribution in comparison to placebo for the treatment of non-IPF PF-ILD (0.50 ± 0.16, on a scale from -1 to 1) and SSc-ILD (0.40 ± 0.12), diseases which were considered as very severe and with high unmet needs. The drug was perceived as a treatment that provides an added therapeutic benefit for patients (0.06-0.07), given its proven clinical efficacy (0.05-0.06), slight improvements in patient-reported outcomes (0.01-0.02), and similar safety profile than placebo (-0.04-0.00), which will likely be positioned as a recommended therapy in the next clinical practice guidelines updates. Under this increasingly used methodology, nintedanib has shown to provide a positive value estimate for non-IPF PF-ILD and SSc-ILD when compared to placebo in Spain.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Interstitial lung diseasesMulti-criteria decision analysisPulmonary fibrosisSystemic sclerosisDecision Support TechniquesDisease ProgressionHumansIndolesLung Diseases, InterstitialReproducibility of Resultsresearch article35912833open accessEnfermedades Pulmonares IntersticialesTécnicas de Apoyo para la Decisión10.1017/S02664623220004591471-6348https://www.cambridge.org/core/services/aop-cambridge-core/content/view/1EE157EE9CC5B41E0E0C161C82B74850/S0266462322000459a.pdf/div-class-title-a-multi-criteria-decision-analysis-on-the-value-of-nintedanib-for-interstitial-lung-diseases-div.pdf